Rhabdomyolysis in a Long-Term Statin User Without Traditional Risk Factors: A Case Report
Authors:
Open Access
- 27 September 2023
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 15 (9) , e46069
Abstract
We report a rare case of rhabdomyolysis in a 64-year-old man who had been receiving long-term statin therapy for hyperlipidemia. The patient initially presented with symptoms of acute appendicitis, which later progressed to acute renal failure and rhabdomyolysis. No commonly identified risk factors for rhabdomyolysis, including drug interactions and statin doses, were observed. The patient was urgently admitted to the intensive care unit where the relevant medications were discontinued in a timely manner and infusion resuscitation was performed. Renal function and serum creatine kinase levels gradually stabilized without the need for hemodialysis. After four days, the patient was transferred to a general ward and was fully discharged from the hospital 13 days after admission. This case highlights the importance of considering rhabdomyolysis as a possible complication among patients receiving statin therapy, even in the absence of traditional risk factors.Keywords
This publication has 17 references indexed in Scilit:
- RhabdomyolysisDisease-a-Month, 2020
- A Klebsiella pneumoniae liver abscess presenting with myasthenia and tea-colored urineMedicine, 2017
- Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phaseThe Lancet, 2017
- Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement NetworkPharmacoepidemiology and Drug Safety, 2012
- The Role of OATP1B1 and BCRP in Pharmacokinetics and DDI of Novel StatinsCardiovascular Therapeutics, 2011
- Risk Factors and Drug Interactions Predisposing to Statin-Induced MyopathyDrug Safety, 2010
- Impact of OATP transporters on pharmacokineticsBritish Journal of Pharmacology, 2009
- Role of OATP Transporters in the Disposition of DrugsPharmacogenomics, 2007
- Calcium Channel Blocker Class Heterogeneity: Select Aspects of Pharmacokinetics and PharmacodynamicsThe Journal of Clinical Hypertension, 2005
- Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering DrugsJAMA, 2004